MONTCLAIR, N.J., Nov. 14, 2012 /PRNewswire/ -- MetaStat, Inc. ("MetaStat" or the "Company") (OTCBB: MTST), a life science company focused on the development and commercialization of proprietary clinical diagnostics that predict the probability of systemic hematogenous (blood borne) metastasis, as well as companion therapeutics to prevent this deadly spread, today announced that its common stock has been approved for quotation on the OTC Bulletin Board ("OTCBB") commencing with the start of trading on November 14, 2012.
Warren C. Lau, President and Chief Executive Officer of MetaStat, commented on the OTCBB listing, "We went through a diligent and thorough review process by FINRA to attain the Bulletin Board listing. We are extremely pleased to provide investors increased visibility and transparency that the Bulletin Board trading platform provides."
About MetaStat, Inc.
MetaStat was formed to allow cancer patients to benefit from the latest discoveries in how cancer spreads through the bloodstream to other organs in the body in a process called metastasis. Our mission is to become an industry leader in the emerging field of personalized cancer therapy. We intend to help clinicians better "customize" cancer treatment decisions by positively identifying high-risk patients who need aggressive therapy and by sparing low-risk patients from the harmful side effects and expense of chemotherapy and/or radiation therapies. Additionally, we are developing companion therapeutics to work in conjunction with our diagnostic products.
We believe our MetaSite Breast and MenaCalc Breast diagnostic product lines will accurately predict the probability that breast cancer will systemically metastasize. Further, we believe our MenaCalc diagnostic platform may be applicable in up to 80% of all solid tumor cancers, including prostate, lung, colorectal, head and neck, and pancreatic. As such, we believe our diagnostic products represent a significant breakthrough for cancer patients and their doctors because metastasis is responsible for 90% of fatalities from solid epithelial cancers. Most significantly, we believe our MenaBloc technology provides us with targets of intervention in key pathways for the development of therapeutics that may preemptively reduce or eliminate metastasis.
Our technology platform(s) and corresponding products are the result of over 15 years of collaboration involving four scientific/academic institutions. We believe we are unique and differentiated in the marketplace because our discoveries are based on direct microscopic visualization of living, functioning tumors in vivo and we have the ability to specifically isolate and thus characterize the behavior, genetics and mechanics of these highly metastatic cells as they migrate to and penetrate blood vessels, where they are subsequently carried away to establish distant site tumors.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
For More Information,
Warren C. Lau
President & CEO
SOURCE MetaStat, Inc.